Skip to content
INTERLACE Study Boosts Cervical Cancer Survival episode artwork

Feb 28, 2024 18 min

INTERLACE Study Boosts Cervical Cancer Survival

from OncTimes Talk

A marked improvement in the outlook for patients with locally advanced cervical cancer has been achieved thanks to a neoadjuvant regimen using standard anti-cancer drugs added to usual therapy. At the ESMO Congress 2023 held in Madrid, Spain, Mary McCormack, PhD, MBBS, FRCR, Consultant Clinical Oncologist at University College London Hospitals, reported findings from the GCIG INTERLACE randomized Phase III trial of induction chemotherapy. This involved the use of carboplatin with paclitaxel for 6 weeks immediately before standard chemoradiotherapy. After the conference, OncTimesTalk's correspondent Peter Goodwin visited McCormack to find out more about the clinical implications arising from the INTERLACE study.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

INTERLACE Study Boosts Cervical Cancer Survival

0:00 18:14

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OncTimes Talk?

This episode is 18 minutes long.

When was this OncTimes Talk episode published?

This episode was published on February 28, 2024.

Can I download this OncTimes Talk episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.